Target Price | €44.71 |
Price | €38.31 |
Potential | 16.71% |
Number of Estimates | 18 |
18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €44.71. This is 16.71% higher than the current stock price. The highest price target is €50.45 31.70% , the lowest is €38.31 0.01% . | |
A rating was issued by 24 analysts: 13 Analysts recommend Qiagen to buy, 11 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 16.71% . Most analysts recommend the Qiagen stock at Purchase. |
24 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 4.11% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 8.08% , the lowest is €1.7b 2.21% .
This results in the following potential growth metrics:
2024 | €1.7b | 0.66% |
---|---|---|
2025 | €1.8b | 7.37% |
2026 | €1.9b | 5.70% |
2027 | €2.0b | 6.73% |
2028 | €2.3b | 12.10% |
2029 | €2.4b | 7.26% |
2030 | €2.8b | 16.45% |
24 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €664m . This is 41.72% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €745m 59.11% , the lowest is €581m 24.07% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €425m | 10.65% |
---|---|---|
2025 | €664m | 56.08% |
2026 | €720m | 8.47% |
2027 | €778m | 8.11% |
2028 | €816m | 4.88% |
2029 | €841m | 3.00% |
2024 | 25.51% | 9.92% |
---|---|---|
2025 | 37.08% | 45.38% |
2026 | 38.05% | 2.62% |
2027 | 38.54% | 1.29% |
2028 | 36.06% | 6.43% |
2029 | 34.63% | 3.97% |
27 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €438m . This is 39.20% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €480m 52.44% , the lowest is €415m 31.86% .
This results in the following potential growth metrics and future Net Margins:
2024 | €70.5m | 75.51% |
---|---|---|
2025 | €438m | 521.77% |
2026 | €475m | 8.31% |
2027 | €521m | 9.88% |
2028 | €572m | 9.69% |
2029 | €597m | 4.45% |
2024 | 4.23% | 75.67% |
---|---|---|
2025 | 24.47% | 479.08% |
2026 | 25.08% | 2.49% |
2027 | 25.82% | 2.95% |
2028 | 25.26% | 2.17% |
2029 | 24.60% | 2.61% |
27 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.02 . This is 41.26% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.21 54.55% , the lowest is €1.91 33.57% .
This results in the following potential growth metrics and future valuations:
2024 | €0.32 | 75.19% |
---|---|---|
2025 | €2.02 | 531.25% |
2026 | €2.19 | 8.42% |
2027 | €2.40 | 9.59% |
2028 | €2.64 | 10.00% |
2029 | €2.75 | 4.17% |
Current | 26.79 | 81.81% |
---|---|---|
2025 | 18.96 | 29.22% |
2026 | 17.50 | 7.70% |
2027 | 15.93 | 8.97% |
2028 | 14.52 | 8.85% |
2029 | 13.90 | 4.27% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.88 and an P/S ratio of 4.65 .
This results in the following potential growth metrics and future valuations:
Current | 5.08 | 11.65% |
---|---|---|
2025 | 4.88 | 3.94% |
2026 | 4.62 | 5.39% |
2027 | 4.33 | 6.30% |
2028 | 3.86 | 10.80% |
2029 | 3.60 | 6.77% |
2030 | 3.09 | 14.13% |
Current | 4.84 | 11.77% |
---|---|---|
2025 | 4.65 | 3.95% |
2026 | 4.40 | 5.39% |
2027 | 4.12 | 6.30% |
2028 | 3.68 | 10.79% |
2029 | 3.43 | 6.77% |
2030 | 2.94 | 14.13% |
Analyst | Rating | Action | Date |
---|---|---|---|
UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Feb 07 2025 |
Analyst Rating | Date |
---|---|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Feb 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.